Wider Access To Naloxone Overdose Medication On Tap In Meeting
This article was originally published in The Tan Sheet
Behind-the-counter placement of opioid overdose treatment does not resonate with FDA, even as it wants to broaden availability. Naloxone administration has increased among non-medical personnel, which may be a reason FDA wants to discuss broader use of the product.
You may also be interested in...
FDA considers switching some prescription “antidotes” to restricted nonprescription status so consumers who can self-identify their need for the drugs and who previously had a prescription can easily access them during life-threatening events, says CDER Director Janet Woodcock.
Six supplement categories based on submission content will be created with review goals between three and 10 months.
The six months of additional exclusivity from US FDA’s CGT program appears to have kept some generic sponsors from the market, and didn’t even prompt others to enter quickly, but use of the competitive generic exclusivity program continues to grow.